AVIV, July 27 (Reuters) – Teva Pharmaceutical Industries has agreed to purchase Allergan's generics business for $40.5 billion, of which $33.75 billion in cash, the remainder card-to-card, in a deal that will make the Israeli company one of the largest pharmaceutical groups in the world.
Following the deal, the largest in Israeli corporate history, Teva promptly withdrew a hostile $40 billion offer for Mylan, a deal that was opposed by a Dutch foundation, a Mylan shareholder.
The deal will also allow Dublin-based Allergan, the third largest US generic drug maker, to focus on brand-name drugs and reduce debt.
The acquisition is just the latest in a growing wave of healthcare deals since early 2014. Globally, M&A in the industry has totaled $398.5 billion year-to-date through July 23. , the 80% more than a year earlier, according to Thomson Reuters data.
On the site www.reuters.it other Reuters news in Italian. Top news also on www.twitter.com/reuters_italia
_____________________________________________________________________
The Israeli could ask for Allergan generics.
THE
Israeli generics maker Teva is in advanced talks with Allergan to acquire its generics business at 40.45bn $ according to Bloomberg. The voices of a separation of generics, whose margins are only 50% (against 80% for products under patent), in a separate entity had been analyzed, as a precondition for a divestment and, in fact, the transaction could be announced this week.
Allergan was bought last year by Actavis, which revived its name and created a $20 billion group of come in . But generic drugs account for less than a third of sales and <allergan è meglio conosciuta per Botox e Namenda contro il morbo di Alzheimer. Per Teva, che non è riuscita finora a comprare Mylan pur offrendo 40 miliardi, sarebbe una via d’uscita onorevole
Les Echos.fr CATHERINE DUCRUET / JOURNALISTS |
Related news: Farmacêutica Allergan compra norte-americana Naurex por US$ 560 milhões
Pharmaceutical: Teva tries again with Mylan, upwards offer up to at least 43 billion $
